Interventions to improve the quality of screening-related colonoscopy: protocol for a systematic review and network meta-analysis of randomised controlled trials

Rishad Khan,1 Marcus Vaska,2 Yibing Ruan3,4, Rishi Bansal,1 Nikko Gimpaya,1 Michael A Scaffidi,5 Darren Brenner6,7,8 G I Leontiannis,7 Samir C Grover,1 Nauzer Forbes1,6,8

ABSTRACT

Introduction Colonoscopy quality can vary depending on endoscopist-related factors. Quality indicators, such as adenoma detection rate (ADR), have been adopted to reduce variations in care. Several interventions aim to improve ADR, but these fall into several domains that have traditionally been difficult to compare. We will conduct a systematic review and network meta-analysis of randomised controlled trials evaluating the efficacies of interventions to improve colonoscopy quality and report our findings according to clinically relevant interventional domains.

Methods and analysis We will search MEDLINE (Ovid), PubMed, EMBASE, CINAHL, Web of Science, Scopus and Evidence-Based Medicine from inception to September 2022. Four reviewers will screen for eligibility and abstract data in parallel, with two accordant entries establishing agreement and with any discrepancies resolved by consensus. The primary outcome will be ADR. Two authors will independently conduct risk of bias assessments. The analyses of the network will be conducted under a Bayesian random-effects model using Markov-chain Monte-Carlo simulation, with 10 000 burn-ins and 100 000 iterations. We will calculate the ORs and corresponding 95% credible intervals of network estimates with a consistency model. We will report the impact of specific interventions within each domain against standard colonoscopy. We will perform a Bayesian random-effects pairwise meta-analysis to assess heterogeneity based on the I² statistic. We will assess the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluation framework for network meta-analyses.

Ethics and dissemination Our study does not require research ethics approval given the lack of patient-specific data being collected. The results will be disseminated at national and international gastroenterology conferences and peer-reviewed journals.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- A comprehensive search strategy will be employed to capture all relevant randomised controlled trials (RCTs) of interventions to answer our study question.
- The certainty of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation framework.
- Compared with prior network meta-analyses (NMAs) reporting comparisons across multiple domains of interventions in screening colonoscopy, our approach is strengthened by the performance of an all-encompassing NMA of RCTs reported by domains, where the efficacies of similar interventions (for instance, intraprocedural techniques) are compared.
- A limitation of our approach is the exclusion of observational studies which could potentially miss important novel approaches, technologies or devices not yet studied in the form of a randomised trial.
- While our choice to exclude conference abstracts was deliberate given their potential for unclear reporting of methodology, a limitation of this choice is ensuring potential publication bias; to mitigate this, we will test for evidence of publication bias.

INTRODUCTION

An estimated 150 000 new cases of colorectal cancer (CRC) and 50 000 associated deaths were estimated to occur in 2021.1 While resection of premalignant adenomatous polyps identified on screening-related colonoscopy has been demonstrated to decrease mortality from CRC,2,3 colonoscopy quality can vary significantly based on endoscopist-related factors.4 Consequently, several quality indicators have been widely adopted to improve colonoscopy quality and reduce variations in care.5–8 In addition, these quality indicators aim to minimise risk of serious adverse events (AEs) in colonoscopy, which, though rare, can occur.9
Adenoma detection rate (ADR), defined as the proportion of screening-related colonoscopies during which one or more adenoma is detected, is arguably the most well-established colonoscopy quality indicator. A strong argument for the use of ADR as a primary quality indicator is its established inverse correlations with postcolonoscopy CRC (PCCRC) and CRC-related death. Despite its importance, reported ADRs vary widely between endoscopists due to modifiable and unmodifiable factors. Furthermore, there is an absence of clear evidence-based guidance regarding strategies to improve ADR. Given the importance and endoscopist-level variability in ADR as well as other colonoscopy quality metrics, such as cecal intubation rate (CIR), there is an urgent need to systematically characterise colonoscopy quality improvement strategies.

Several interventions exist that aim to improve ADR. Broadly, these can be categorised into several domains, including preprocedural and periprocedural considerations (eg, optimised bowel cleansing and sedation regimens), endoscopist-directed interventions (eg, directed audit and feedback or educational courses), intra-procedural techniques (eg, dynamic positional changes or second-look examination), endoscopy technologies (eg, advanced imaging or computer-aided detection), and additive substances (eg, hyoscine-n-butylbromide).

Prior meta-analyses have assessed the impacts of these strategies on ADR and other colonoscopy quality metrics. Few studies, however, have compared the relative impacts of multiple similar interventions using network meta-analyses (NMAs). The NMAs that exist have reported comparisons across several interventional domains, resulting in substantial heterogeneity in interventions, patient populations and study methodology. These limitations create challenges in interpreting the data and preclude the provision of meaningful guidance for practising endoscopists regarding colonoscopy quality improvement. To address these gaps, we will conduct an overarching systematic review and NMA of randomised controlled trials (RCTs) evaluating interventions to improve colonoscopy quality.

**METHODS**

**Overview and objectives**

We will conduct this systematic review and NMA according to the guidelines for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions. Our protocol has been registered a priori on PROSPERO (CRD42021291814).

The primary objective of this study is to determine the impact of various interventions on ADR when compared with standard colonoscopy. The secondary objectives are to determine the impact of the same interventions, on other quality indicators and detection parameters, including polyp detection rate (PDR), ADR subtypes (including but not limited to sessile serrated lesion detection rate and locational ADR), missed adenoma rate, CIR, withdrawal time, sedation requirements, patient satisfaction metrics, AE rates and unplanned healthcare encounters (UHEs), in addition to assessing these comparisons within clinically relevant subgroups determined a priori and described below. No research ethics approval is required for this study given the lack of patient-specific data being collected.

**Eligibility criteria**

We will include studies that meet all of the following criteria: (1) patients are adults (age ≥ 18) undergoing screening-related colonoscopy; (2) interventions include any of the following categories or any other category deemed to be relevant: preprocedural and periprocedural parameters (eg, bowel preparation, numbers and types of observers, sedation regimens), endoscopist-directed interventions (eg, directed audit and feedback, educational courses), intra-procedural techniques (eg, dynamic positional changes, second-look segmental examination, retroflexed segmental examination, water immersion), endoscopy technologies (eg, advanced imaging modalities, CADe), disposable assistive devices (eg, cuffs, rings, caps) and additive substances (eg, hyoscine-n-butylbromide, natural/herbal additives); (3) the comparator is one of either (A) ‘standard colonoscopy’ (SC), defined as white light colonoscopy performed with high-definition colonoscopes in primary a screening-related population (defined below) without the aid of strategies used in intervention groups specific to the domain being assessed or (B) any of the other interventions described; (4) one or more of the primary or secondary outcomes is reported (ADR or its subtypes, PDR, CIR, withdrawal time, sedation requirements, AE rates, UHE rates); and (5) the study type is an RCT. Studies will be considered to assess a screening population if they met all the following criteria: (A) ≤ 15% of the study cohort falls outside the age range 40–80; (B) ≤ 15% of the cohort are inpatients at the time of the procedure; (C) ≤ 15% of the cohort is undergoing colonoscopy for non-screening-related indications, such as active gastrointestinal symptoms or surveillance related to inflammatory bowel disease.

A study will be excluded from the final review if it meets any of the following criteria: (1) it is an observational study, case report or series, narrative or systematic review, or meta-analysis; (2) the comparator is either unclear or not considered to represent SC for the purposes of comparisons within the domain in question; (3) there is an absence of any relevant reported outcomes; (4) it assesses upper endoscopies and/or flexible sigmoidoscopies as part of the study cohort; (5) it assesses colonoscopy outcomes exclusively in trainees; (6) it assesses colonoscopies in a high-risk population such as those with hereditary polyposis syndromes; (7) it was published prior to the year 2000, as it may contain data from non-high-definition colonoscopies and (8) it is not published in full manuscript form.
Search strategy and terms
We designed a comprehensive search strategy with a health research librarian (MV) to query the electronic databases MEDLINE (Ovid), PubMed, EMBASE, CINAHL, Web of Science, Scopus and Evidence-Based Medicine from inception to September 2022. Each interventional domain outlined above will inform a separate search. A combination of free-text and Medical Subject Heading (MeSH) terminology will be employed in the search strategy, along with appropriate synonyms and spelling variations. The full electronic search strategy is provided in the online supplemental materials.

Study selection and data abstraction
All citations will be imported into Covidence (Melbourne, Australia) and all duplicate entries will be removed. A team of 4 reviewers (RK, RB, NG and MAS) will perform initial screening, full-text exclusion and data abstraction. Each reviewer will be assigned approximately an equal number of citations at each screening stage, with a vote of ‘both include’ or ‘both exclude’ by the two reviewers resulting in inclusion or exclusion, respectively. All potential discrepancies will be resolved by a third vote by either senior study author (SCG or NF).

All included citations from the first stage will undergo duplicate full-text assessment with a subsequent inclusion or exclusion by two reviewers of the same team of four (RK, RB, NG and MAS), with discrepancies again resolved by the senior authors. Data will then be abstracted in duplicate by two authors (RK and RB) into standardised forms containing: (1) study identification (eg, authorship, year of publication, country of origin), (2) study design parameters and risk of bias assessments, (3) endoscopist demographics, (4) patient demographics (eg, age, sex, comorbidities), (5) descriptions of the intervention and comparators, (6) bowel preparation regimens and (7) outcomes. We will also collect data on relevant subgroups where available.

Outcome definitions
The primary outcome is ADR. Secondary outcomes are PDR, ADR subtypes, adenoma per colonoscopy (APC), APC subtypes, missed adenoma rates, CIR, withdrawal time, sedation requirements, AE rates, UHE rates and patient satisfaction. ADR and APC subtypes will include right-sided ADR, defined as the proportion of colonoscopies in which at least one adenoma is found in the right colon,

Statistical analysis, sensitivity and subgroup analyses
We will perform a Bayesian random-effects pairwise meta-analysis to assess heterogeneity based on the $I^2$ statistic. If substantial heterogeneity is observed, we will address heterogeneity by carrying out meta-regression on relevant covariates using random effects models and by excluding studies. We will assess the transitivity assumption of the NMA with two approaches. First, we will examine the distribution of effect modifiers of the interventions across studies, such as sex and/or gender, family history of polyps and/or CRC, differences in procedural indication, quality of bowel preparation and definitions of ‘standard’ colonoscopy, to make sure that no significant differences exist in these factors. Second, we will carry out a test of inconsistency to determine whether there is statistical evidence of overall inconsistency. The presence of inconsistency will be addressed with either subgroup analysis or meta-regression.

The main analyses of the network will be conducted under a Bayesian random-effects model using Markov chain Monte-Carlo simulation, with 10 000 burn-ins and 100 000 iterations. We will calculate the ORs and corresponding 95% credible intervals of network estimates with a consistency model. The ranking probabilities of the interventional domains will be evaluated with a plot of surface under the cumulative ranking curves and a league table of the relative effects between all interventions. Publication bias will be evaluated with a comparison-adjusted funnel plot. Local incoherence will be assessed by comparing the direct estimates to the indirect estimates obtained through a node-splitting method. All analysis will be performed using the BUGSnNet and gemtc R packages.

For the primary analyses, results will be separated into interventional domains previously outlined: procedural and periprocedural parameters, endoscopist-directed interventions, intraprocedural techniques, endoscopy technologies, disposable assistive devices, additive substances or other interventions not foreseen by our study team that could feasibly comprise their own homogeneous domain. These domains are summarised in table 1. We will report the impact of specific interventions within each domain against standard colonoscopy for each available outcome.

We will perform sensitivity analyses to assess: low (<25%) vs high study attrition/ dropout rates, results from studies published prior to 2015 vs in 2015 or later (to account for gradual overall improvements in colonoscopy quality over time), results from North American versus European versus Asian studies, results from per-protocol versus intention-to-treat analyses, results from studies with clear and similar descriptions of comparator arms versus others, results from only those studies with even more restrictive screening-related criteria (<5% rather than <15% as described above), and results from all studies performed using the Cochrane Risk of Bias tool, version 2 (RoB 2). Discrepancies will be resolved by consensus.

Risk of bias
Two authors (RK and RB) will conduct risk of bias assessments in parallel for all studies included in the final review. Assessment of randomised studies will be
versus only those without high risks of bias according to RoB 2.28 We will also perform subgroup analyses, where possible, to assess: relevant patient subgroups (including age, sex, ethnicity/race and comorbidities), indications for colonoscopy (including faecal immunochemical test-positive patients vs surveillance vs initial screening vs others), bowel preparation quality, extent of trainee participation, sedation practices, colonoscopy completion rates and endoscopist specialty and experience.

### Certainty of the evidence

We will assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework32 and will specifically follow

---

| Domain                          | Potential interventions                          | Potential comparators                      |
|--------------------------------|------------------------------------------------|--------------------------------------------|
| Periprocedural parameters      | Split dose bowel preparation                    | Day before bowel preparation              |
|                                | Split dose bowel preparation                    | Same day bowel preparation                 |
|                                | Sodium picosulphate bowel preparation           | Polyethylene glycol bowel preparation      |
|                                | Simethicone (in bowel preparation)              | Standard bowel preparation                 |
|                                | Patient education on bowel preparation         | No patient education                       |
|                                | Propofol sedation                              | Opioid and benzodiazepine sedation        |
|                                | Nurse observer or other second observer         | Single observer                            |
| Endoscopist parameters         | Educational interventions                       | No interventions                           |
|                                | Audit and feedback (report cards)              | No audit and feedback (report cards)       |
| Intraprocedural techniques     | Water exchange or water immersion               | Air or CO2 insufflation                    |
|                                | Dynamic position changes                       | No position changes                        |
|                                | Second inspection on forward view              | Standard inspection                        |
|                                | Right sided retroflexion                       | Second inspection on forward view          |
|                                | Right sided retroflexion                       | Standard inspection                        |
|                                | ‘Two-handed’ technique (with assistant)        | ‘One-handed’ technique                     |
|                                | Resection of polyps on insertion               | Resection of polyps on withdrawal          |
|                                | >9 min withdrawal time                         | 6–9 min withdrawal time                    |
|                                | Monitoring of withdrawal time                  | No monitoring of withdrawal time           |
|                                | Segmental timed withdrawal                     | Standard inspection with 6–8 min total withdrawal |
| Endoscopic technologies        | Linked colour imaging (LCI)                    | Narrow-band imaging (NBI)                 |
|                                | LCI                                            | White light imaging                        |
|                                | NBI                                            | White light imaging                        |
|                                | i-Scan imaging                                 | White light imaging                        |
|                                | Autofluorescence imaging                       | White light imaging                        |
|                                | Any enhanced optical imaging                   | Standard colonoscopy                       |
|                                | High-definition colonoscopy                    | Standard colonoscopy                       |
|                                | Artificial intelligence/computer-aided detection| Standard colonoscopy                       |
|                                | Use of ultrathin colonoscopes                  | Standard colonoscopy                       |
|                                | Full spectrum endoscopy                        | Standard colonoscopy                       |
| Disposable assistive devices   | Endocuff-assisted colonoscopy                  | Standard colonoscopy                       |
|                                | Endorings-assisted colonoscopy                 | Standard colonoscopy                       |
|                                | Endocuff vision (ECV)-assisted colonoscopy     | Standard colonoscopy                       |
|                                | ECV-assisted colonoscopy                       | AmplifEYE-assisted colonoscopy             |
|                                | AmplifEYE-assisted colonoscopy                 | Standard colonoscopy                       |
|                                | Cap-assisted colonoscopy                       | Standard colonoscopy                       |
| Additive substances            | Methylene blue                                 | No additives                               |
|                                | Hyoscine-N-butylbromide                        | No additives                               |
|                                | Peppermint oil                                 | No additives                               |
their guidance for NMA. Two reviewers with experience in using GRADE (GIL and NF) will independently and in a blinded fashion (with interventions and comparator groups concealed) rate each GRADE domain for each comparison, including the overall risk of bias, publication bias, inconsistency, indirectness, imprecision, incoherence and violation of transitivity. To help inform the ultimate GRADE ratings, all study authors who perform colonoscopy will be surveyed individually to provide their minimum clinically meaningful thresholds for all outcomes, in absolute differences.

**Patient and public involvement**

No patients or public were involved with study design, and none will be involved in the interpretation of results.

**DISCUSSION**

This systematic review and NMA will provide a contemporary evaluation of the comparative efficacies of interventions designed to improve colonoscopy quality using the highest available form of input evidence. This study will inform evidence-based guidelines and is a crucial step toward improving patient outcomes.

Although colonoscopy is an extremely common procedure, variations in the quality of screening-related colonoscopy exist can result in incomplete procedures, missed lesions, AEs and/or PCCRC. This is the obligation of endoscopists performing screening-related colonoscopy to be aware of interventions to improve the quality of this procedure. Furthermore, up-to-date knowledge of these interventions is critical to endoscopy unit managers, healthcare decision-makers and gastrointestinal and endoscopy societies to provide recommendations on the best available options to improve care.

Prior meta-analyses have summarised the effects of interventions that aim to improve or optimise colonoscopy quality. However, few studies have attempted to compare the magnitudes of effects of multiple similar interventions by performing NMAs. In the few NMAs that do exist assessing this question, comparisons have been reported across multiple interventional domains, with potential heterogeneity in interventions, patient populations and study methodology. Our study proposes to mitigate these issues by reporting the results of an overarching, all-encompassing NMA of RCTs according to domains, where the efficacies of similar interventions (for instance, intraprocedural techniques) are compared with standard colonoscopy and reported together.

Though our protocol was designed to mitigate sources of bias using rigorous methodology, there are limitations with our approach. Like any meta-analysis, the certainty of pooled estimates is dependent on the quality of input studies. For this reason, we are only including RCTs, which represent the highest starting point for study quality. We acknowledge that this approach will exclude observational studies assessing novel interventions not yet studied in an RCT. Another limitation is the possibility of pooling outcome estimates using variable definitions of ‘standard colonoscopy’ (the comparator) across studies and domains. To mitigate this, we will review study-specific descriptions of comparator arms in detail and perform sensitivity analyses to exclude studies with unclear or dissimilar descriptions of the comparator arm. Finally, we will exclude conference abstracts from being eligible.

Though this decision potentially exposes our study to publication bias, we contend that the lack of detailed methodology often found in conference proceedings can introduce heterogeneity to our findings.

To summarise, we anticipate that our study will bridge an important knowledge gap relating to the relative efficacies of interventions to improve colonoscopy quality. Our results can have an immediate impact on patients and endoscopists and downstream impact on clinical practice guidelines and healthcare decision making. Future research should use these high-quality data to perform cost-effectiveness analyses of interventions within each domain.

**ETHICS AND DISSEMINATION**

Our study does not require research ethics approval given the lack of patient-specific data being collected. The results will be disseminated to local, national and international gastroenterology and endoscopy societies, and submitted to national and international gastroenterology conferences and peer-reviewed journals.

**Author affiliations**

1Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
2Knowledge Resource Service, Alberta Health Services, Calgary, Alberta, Canada
3Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services, Calgary, Alberta, Canada
4Department of Oncology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
5School of Medicine, Queen’s University, Kingston, Ontario, Canada
6Division of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
7Department of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
8Department of Medicine, University of Calgary, Calgary, Alberta, Canada
9Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada

**Twitter**

G I Leontiadis @GriLeont

**Contributors**

NF, SCG and GIL were involved in the conception and design of the study. RK, MV, YR, RB, NG, MAS, DB, GIL, SCG and NF were involved in developing the analysis plan. RK and NF drafted the article. RK, MV, YR, RB, NG, MAS, DB, GIL, SCG and NF critically revised the article for important intellectual content and approved the final version of the article.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

RK has received research funding from AbbVie, Ferring Pharmaceuticals, and Pendopharm. SCG has received research grants and personal fees from AbbVie and Ferring Pharmaceuticals, personal fees from Takeda, educational grants from Janssen, and has equity in Volo Healthcare. NF is a consultant and on the speaker’s bureau for Pentax Medical and Boston Scientific, is a consultant for Pendopharm, and has received research funding from Pentax Medical. All other authors have no relevant conflicts to declare.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.
REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7–33.
2. Levin TR, Cronley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology 2018;155:1383–91.
3. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095–105.
4. Hilsden RJ, Rose SM, Dube C, et al. Defining and applying locally relevant benchmarks for the adenoma detection rate. Am J Gastroenterol 2019;114:1315–21.
5. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Gastrointest Endosc 2015;81:31–53.
6. Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of gastrointestinal endoscopy (ESGE) quality improvement initiative. United European Gastroenterol J 2017;5:309–34.
7. Barclay RL, Vicari JJ, Dougherty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006;355:2533–41.
8. Rees CJ, Thomas Gibson S, Rutter MD, et al. UK key performance indicators and quality assurance standards for colonoscopy. Gut 2016;65:1923–9.
9. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135:1906.e1:1899–906.
10. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298–306.
11. Mazurek M, Murray A, Heitman SJ, et al. Association between endoscopist specialty and colonoscopy quality: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022;20:1931–46.
12. Forbes N, Boyne DJ, Mazurek MS, et al. Association between endoscopist annual procedure volume and colonoscopy quality: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020;18:2192–208.
13. Zawaly K, Rumbolt C, Abou-Setta AM, et al. The efficacy of split-dose bowel preparations for polyp detection: a systematic review and meta-analysis. Am J Gastroenterol 2019;114:884–92.
14. Aziz M, Weissman S, Fatima R, et al. Impact of propofol sedation versus opioid/benzodiazepine sedation on colonoscopy outcomes: a systematic review with meta-analysis. Endosc Int Open 2020;8:E701–7.
15. Bishay K, Causada-Calvo N, Scaffidi MA, et al. Associations between endoscopist feedback and improvements in colonoscopy quality indicators: a systematic review and meta-analysis. Gastrointest Endosc 2020;92:1030–40.
16. Causada-Calvo NS, Gonzalez-Moreno EI, Bishay K, et al. Educational interventions are associated with improvements in colonoscopy quality indicators: a systematic review and meta-analysis. Endosc Int Open 2020;8:E1201–31.
17. Lee S-W, Chang JH, Ji J-S, et al. Effect of dynamic position changes on adenoma detection during colonoscopy withdrawal: a randomized controlled multicenter trial. Am J Gastroenterol 2016;111:83–9.
18. Desai M, Bilal M, Hamade N, et al. Increasing adenoma detection rates in the right side of the colon with 180° retroflexion with a second forward view: a systematic review. Gastrointest Endosc 2019;89:453–9.
19. Spadaccini M, Iannone A, Maselli R, et al. Computer-Aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021;6:793–802.
20. Forbes N, Hilsden RJ, Ruan Y, et al. Endocuff vision improves adenoma detection rate in a large screening-related cohort. Endosc Int Open 2019;7:E1583–92.
21. Rex DK, Kessler WR, Sagi SV, et al. Impact of a ring-fitted cap on insertion time and adenoma detection: a randomized controlled trial. Gastrointest Endosc 2020;91:115–20.
22. Forbes N, Frehlich L, Borgaonkar M, et al. Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine-n-butylbromide (Buscopan) During Gastrointestinal Endoscopy. J Can Assoc Gastroenterol 2021;4:259–68.
23. Facciorusso A, Triantafyllou K, Murad MH, et al. Compared abilities of endoscopic techniques to increase colon adenoma detection rates: a network meta-analysis. Clin Gastroenterol Hepatol 2019;17:2439–54.
24. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanation. Ann Intern Med 2019;171:261–72.
25. Samadder NJ, Curtin K, Tuohy TFM, et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 2014;146:950–60.
26. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002;12:1–9.
27. Strum WB. Colorectal adenomas. N Engl J Med 2016;374:1065–75.
28. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions, 2011.
29. Béliveau A, Boyne DJ, Slater J, et al. BUGSnnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med Res Methodol 2019;19:196.
30. van Valkenhoef G, Kuiper J. Package ‘gemtc’ 2021.
31. Mathews SC, Zhao N, Holub JL, et al. Improvement in colonoscopy quality metrics in clinical practice from 2000 to 2014. Gastrointest Endosc 2019;90:651–5.
32. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
33. Brigardello-Petersen R, Ronner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol 2018;93:36–44.
34. Brigardello-Petersen R, Guyatt GH, Mustafa RA, et al. GRADE guidelines 33: addressing imprecision in a network meta-analysis. J Clin Epidemiol 2021;139:49–56.
35. Brigardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. J Clin Epidemiol 2019;108:77–85.
36. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80–97.
## Supplementary Materials 1: Electronic Search Strategy

| #  | Searches                                                                 | Results |
|----|--------------------------------------------------------------------------|---------|
| 1  | "colonoscop*".ab,ti.                                                    | 33211   |
| 2  | Colonoscopy/                                                             | 29245   |
| 3  | 1 or 2                                                                   | 45260   |
| 4  | "adenoma*".ab,ti.                                                       | 88948   |
| 5  | exp Adenoma/                                                             | 104759  |
| 6  | "adenoma detection rate".ab,ti.                                         | 1051    |
| 7  | ADR.ab,ti.                                                               | 9718    |
| 8  | "adverse drug reaction".ab,ti.                                          | 4580    |
| 9  | (ADR not "adverse drug reaction").ab,ti.                                | 8451    |
| 10 | "advanced adenoma detection rate".ab,ti.                                | 42      |
| 11 | AADR.ab,ti.                                                              | 118     |
| 12 | polyp.ab,ti.                                                             | 18041   |
| 13 | polyps.ab,ti.                                                            | 29419   |
| 14 | exp Polyps/                                                              | 33562   |
| 15 | "sessile serrated adenoma detection rate".ab,ti.                        | 8       |
| 16 | SSADR.ab,ti.                                                             | 6       |
| 17 | "polyp detection rate".ab,ti.                                           | 429     |
| 18 | "cancer detection".ab,ti.                                               | 11561   |
| 19 | "early detection of cancer".ab,ti.                                       | 1389    |
| 20 | (detect* adj3 cancer).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] | 70007   |
| 21 | exp "Early Detection of Cancer"/                                        | 31999   |
| 22 | note/ or editorial/ or letter/ or Comment/ or news/ or (note or editorial or letter or Comment or news).pt. | 2231129 |
| 23 | 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 | 265114 |
| 24 | 3 and 23 | 16790 |
| 25 | exp Congresses as Topic/ | 31500 |
| 26 | limit 24 to (clinical conference or consensus development conference or consensus development conference, nih) | 25 |
| 27 | "conference abstract" .ab,ti. | 2292 |
| 28 | "conference" .ab,ti. | 79401 |
| 29 | "proceeding" .ab,ti. | 64957 |
| 30 | "professional meeting" .ab,ti. | 313 |
| 31 | 25 or 27 or 28 or 29 or 30 | 158196 |
| 32 | 24 and 31 | 46 |
| 33 | 26 or 32 | 69 |
| 34 | 24 not 33 | 16721 |
| 35 | 24 not 22 | 15466 |
| 36 | 34 or 35 | 16790 |
| 37 | limit 36 to (comment or editorial or letter or news) | 1324 |
| 38 | 24 not 37 | 15466 |
| 39 | 35 or 38 | 15466 |
| 40 | 34 or 39 | 16790 |
| 41 | ((randomized controlled trial or controlled clinical trial).pt. or (Randomized or placebo or randomly or trial or groups).ab. or drug therapy.fs.) not (exp animals/ not exp humans/) | 4567596 |
| 42 | Randomized Controlled Trials as Topic/ | 152453 |
| 43 | randomized controlled trial/ | 557617 |
| 44 | Random Allocation/ | 106515 |
| 45 | Double Blind Method/ | 169815 |
|   |   |   |
|---|---|---|
| 46 | Single Blind Method/ | 31549 |
| 47 | clinical trial/ | 533613 |
| 48 | clinical trial, phase i.pt. | 23093 |
| 49 | clinical trial, phase ii.pt. | 36959 |
| 50 | clinical trial, phase iii.pt. | 19874 |
| 51 | clinical trial, phase iv.pt. | 2263 |
| 52 | controlled clinical trial.pt. | 94677 |
| 53 | randomized controlled trial.pt. | 557617 |
| 54 | multicenter study.pt. | 314322 |
| 55 | clinical trial.pt. | 533613 |
| 56 | exp Clinical Trials as topic/ | 369924 |
| 57 | or/42-56 | 1491358 |
| 58 | (clinical adj trial$).tw. | 424865 |
| 59 | ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw. | 185948 |
| 60 | PLACEBOS/ | 35873 |
| 61 | placebo$.tw. | 232521 |
| 62 | randomly allocated.tw. | 32782 |
| 63 | (allocated adj2 random$).tw. | 36321 |
| 64 | or/58-63 | 712895 |
| 65 | 57 or 64 | 1796239 |
| 66 | case report.tw. | 354010 |
| 67 | letter/ | 1168635 |
| 68 | historical article/ | 367491 |
| 69 | or/66-68 | 1872644 |
| 70 | 65 not 69 | 1755622 |
| 71 | 41 or 70 | 5113874 |
| 72 | Meta-Analysis as Topic/ | 20756 |
|   | Description                                                                 | Count |
|---|------------------------------------------------------------------------------|-------|
| 73 | meta analy$.tw.                                                              | 222949|
| 74 | metaanaly$.tw.                                                               | 2374  |
| 75 | Meta-Analysis/                                                               | 152103|
| 76 | (systematic adj (review$1 or overview$1)).tw.                               | 231900|
| 77 | exp Review Literature as Topic/                                              | 18682 |
| 78 | or/72-77                                                                     | 381309|
| 79 | cochrane.ab.                                                                 | 109130|
| 80 | embase.ab.                                                                   | 123072|
| 81 | (psychlit or psyclit).ab.                                                     | 916   |
| 82 | (psychinfo or psycinfo).ab.                                                  | 47683 |
| 83 | (cinahl or cinhal).ab.                                                       | 37041 |
| 84 | science citation index.ab.                                                   | 3421  |
| 85 | bids.ab.                                                                     | 597   |
| 86 | cancerlit.ab.                                                                | 636   |
| 87 | or/79-86                                                                     | 198616|
| 88 | reference list$.ab.                                                          | 20307 |
| 89 | bibliograph$.ab.                                                             | 20455 |
| 90 | hand-search$.ab.                                                             | 7824  |
| 91 | relevant journals.ab.                                                        | 1276  |
| 92 | manual search$.ab.                                                           | 5242  |
| 93 | or/88-92                                                                     | 49445 |
| 94 | selection criteria.ab.                                                      | 33383 |
| 95 | data extraction.ab.                                                          | 26834 |
| 96 | 94 or 95                                                                     | 57717 |
| 97 | Review/                                                                      | 2931897|
| 98 | 96 and 97                                                                    | 31378 |
| 99 | Comment/                                                                     | 950364|
|   |   |   |
|---|---|---|
| 100 | Letter/ | 1168635 |
| 101 | Editorial/ | 594488 |
| 102 | animal/ | 7027830 |
| 103 | human/ | 20138000 |
| 104 | 102 not (102 and 103) | 4919100 |
| 105 | or/99-101,104 | 6881661 |
| 106 | 78 or 87 or 93 or 98 | 456526 |
| 107 | 106 not 105 | 433831 |
| 108 | 71 or 107 | 5358988 |
| 109 | 40 and 108 | 4587 |
| 110 | limit 109 to yr="2000 -Current" | 4222 |
| 111 | remove duplicates from 110 | 4216 |